IDMO Growth Opportunity Positioned as the first integrated development and manufacturing organization with end-to-end automated cell therapy production, Cellares offers a turnkey platform (Cell Shuttle) and Smart Factories to scale out global manufacturing. Growth opportunities for business development include co-development and long-term manufacturing partnerships with academic labs, biotech startups, and pharma companies seeking faster process transfer, lower failure rates, and lower costs.

Partnership Pipeline Cellares already operates long-term commercial supply agreements with established cell therapy players and has active collaborations in development stages, supported by high-profile investors. For sales, target similar mid- to late-stage programs needing scalable, compliant manufacturing and guaranteed capacity, offering multi-year supply contracts, tech transfer, and access to the automated platform.

Global Footprint With a U.S. HQ and a commercial-scale IDMO facility, plus plans for a global network of Smart Factories, there is a clear opportunity to help customers scale trials and commercialization regionally. BD touchpoints include regulatory readiness support, regional supply security, and seamless integration with customers’ clinical development timelines.

Capital & Growth The company has demonstrated strong investor backing and a clear path toward larger-scale manufacturing and eventual public listing. This indicates ample capital to fund capacity expansion, making it attractive for partners seeking long-term capacity commitments and co-investment opportunities to secure reliable manufacturing throughput.

Digital & Tech Advantage Cellares’ technology stack emphasizes automation, data integration, and cloud-enabled workflows, creating opportunities to offer ERP/MES integration, digital twin modeling, remote monitoring, and quality/compliance automation to customers, accelerating technology transfer and improving process control.